Rivaroxaban Tablets 2.5mg Technical Specification:
| Product Name: | Rivaroxaban Tablets 2.5mg |
| Brand Name: | Generic |
| Strength: | (2.5mg), (10mg), (15mg), (20mg) |
| Dosage Form: | Tablets (Film-coated) |
| Route of Administration: | Via Oral Route |
| Packing: | 10s, 30s, 100s, 500s |
| Pack Insert/Leaflet: | PIL (Patient Information Leaflet), SmPC (Summary Product Characteristics) |
| Regulatory Documents: | COA, MOA, COPP, FSC, Stability Studies, GMP, CTD Dossier |
| Therapeutic use: | Anticoagulant |
| Indication: | Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary. |
| Storage: | Store at 20° to 25°C (68° to 77°F). Store in dry place protected from light and moisture. |
GENERIC NAME OF THE MEDICINAL PRODUCT:
- Rivaroxaban Tablets 2.5mg
- Rivaroxaban Tablets 10mg
- Rivaroxaban Tablets 15mg
- Rivaroxaban Tablets 20mg
QUALITATIVE AND QUANTITATIVE COMPOSITION:
- Rivaroxaban Tablets 2.5mg
Each Film-coated tablet contains:
Rivaroxaban………2.5mg
Excipients…………..q.s
Colour: Ferric Oxide yellow USP-NF, Titanium Dioxide IP
- Rivaroxaban Tablets 10mg
Each Film-coated tablet contains:
Rivaroxaban………10mg
Excipients…………..q.s
Colour: Red oxide of iron & Titanium Dioxide IP
- Rivaroxaban Tablets 15mg
Each Film-coated tablet contains:
Rivaroxaban………15mg
Excipients…………..q.s
Colour: Red oxide of iron & Titanium Dioxide IP
- Rivaroxaban Tablets 20mg
Each Film-coated tablet contains:
Rivaroxaban………20mg
Excipients…………..q.s
Colour: Ferric Oxide RED USP-NF, Titanium Dioxide IP
THERAPEUTIC INDICATIONS:
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary.
CAUTION & WARNING:
CAUTION:
Read enclosed leaflet before use.
Keep medicine out of reach of children.
SWALLOW WHOLE DO NOT CHEW OR CRUSH.
WARNING: To be sold by retail on the prescription of a Registered Medical Practitioner only.
STORAGE & DOSAGE:
Storage: Store at 20° to 25°C (68° to 77°F)
Store in dry place protected from light and moisture.
Dosage: As directed by the Physician
Attach dispensing label as per end country.
GENERIC NAME OF THE MEDICINAL PRODUCT:
A. Rivaroxaban Tablets 2.5mg
B. Rivaroxaban Tablets 10mg
C. Rivaroxaban Tablets 15mg
D. Rivaroxaban Tablets 20mg
B. Rivaroxaban Tablets 10mg
C. Rivaroxaban Tablets 15mg
D. Rivaroxaban Tablets 20mg
QUALITATIVE AND QUANTITATIVE COMPOSITION:
A. Rivaroxaban Tablets 2.5mg
Each Film-coated tablet contains:
Rivaroxaban………2.5mg
Excipients…………..q.s
Colour: Ferric Oxide yellow USP-NF, Titanium Dioxide IP
B. Rivaroxaban Tablets 10mg
Each Film-coated tablet contains:
Rivaroxaban………10mg
Excipients…………..q.s
Colour: Red oxide of iron & Titanium Dioxide IP
C. Rivaroxaban Tablets 15mg
Each Film-coated tablet contains:
Rivaroxaban………15mg
Excipients…………..q.s
Colour: Red oxide of iron & Titanium Dioxide IP
D. Rivaroxaban Tablets 20mg
Each Film-coated tablet contains:
Rivaroxaban………20mg
Excipients…………..q.s
Colour: Ferric Oxide RED USP-NF, Titanium Dioxide IP
Each Film-coated tablet contains:
Rivaroxaban………2.5mg
Excipients…………..q.s
Colour: Ferric Oxide yellow USP-NF, Titanium Dioxide IP
B. Rivaroxaban Tablets 10mg
Each Film-coated tablet contains:
Rivaroxaban………10mg
Excipients…………..q.s
Colour: Red oxide of iron & Titanium Dioxide IP
C. Rivaroxaban Tablets 15mg
Each Film-coated tablet contains:
Rivaroxaban………15mg
Excipients…………..q.s
Colour: Red oxide of iron & Titanium Dioxide IP
D. Rivaroxaban Tablets 20mg
Each Film-coated tablet contains:
Rivaroxaban………20mg
Excipients…………..q.s
Colour: Ferric Oxide RED USP-NF, Titanium Dioxide IP
THERAPEUTIC INDICATIONS:
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary..
CAUTION & SCHEDULE:
CAUTION: Read enclosed leaflet before use.
KEEP MEDICINE OUT OF REACH OF CHILDREN.
SWALLOW WHOLE DO NOT CHEW OR CRUSH
SCHEDULE: SCHEDULE H: NOT TO BE SOLD BY RETAIL WITHOUT THE PRESCRIPTION OF A REGISTERED MEDICAL PRACTITIONER.
KEEP MEDICINE OUT OF REACH OF CHILDREN.
SWALLOW WHOLE DO NOT CHEW OR CRUSH
SCHEDULE: SCHEDULE H: NOT TO BE SOLD BY RETAIL WITHOUT THE PRESCRIPTION OF A REGISTERED MEDICAL PRACTITIONER.
STORAGE & DOSAGE:
Storage: Store at 20° to 25°C (68° to 77°F)
Store in dry place protected from light and moisture.
Dosage: As directed by the Physician
Attach dispensing label as per end country.
Store in dry place protected from light and moisture.
Dosage: As directed by the Physician
Attach dispensing label as per end country.










